Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2004

View Archived Issues

Depletion of B-cells by humanized anti-CD20 antibody in monkeys

Abatacept shows promise in the treatment of rheumatoid arthritis

Enrollment underway in study of WinRho SDF for dengue hemorrhagic fever

Cangene and DynPort seeking approval of VIG products

Orphan drug status for Efaproxyn

South African HIV trial of VGV-1 commences enrollment

Sculptra receives FDA approval for lipoatrophy

Funding at Pepgen to support advancement of Tauferon

New KSP inhibitors jointly reported by GSK and Cytokinetics

Micrologix Biotech and Strata enter agreement for MBI-226

New histamine H3 ligands and their use in obesity and other disorders

Sigma-Tau presents novel agents for diabetes, obesity, etc.

Orphan drug designation for ambrisentan for PAH

Active Pass researchers describe new antiamyloidogenic agents

Pierre Fabre and Merck & Co. sign agreement for F-50035

Novel CD80 antagonists and their use claimed by Active Biotech

Phase I study begins of IL-13-PE38QQR for newly diagnosed malignant glioma

Novel 5-HT reuptake inhibitors and 5-HT1A/5-HT2A agonists identified at Merck KGaA

NR2B-selective NMDA antagonists newly discovered at Pfizer

SBIR award supports research into proteoglycans in Alzheimer's at ProteoTech

Enrollment completed in phase II study of octreotide implant

Series B financing at Ceregene

BAY-43-9006 receives European orphan drug status for renal cell carcinoma

Emisphere selects formulation of oral heparin

AX-200 set to enter phase II for stroke

GSK provides notice to Inex to terminate topotecan agreement

Cymbalta approved for major depressive disorder

Liver-selective glucocorticoid antagonist for type 2 diabetes therapy

Antioxidant compound effective against arteriosclerosis in rodent allograft model

Novel immunotherapeutic approach to cancer therapy with dendritic cell crosslinking antibody

Exploring effective natural products for Alzheimer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...